{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:51:33Z","timestamp":1785419493498,"version":"3.56.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40257-021-00609-4","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T15:44:00Z","timestamp":1622562240000},"page":"477-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Beh\u00e7et Disease: An Update for Dermatologists"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-0170","authenticated-orcid":false,"given":"Erkan","family":"Alpsoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-5037","authenticated-orcid":false,"given":"Burcin Cansu","family":"Bozca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-7908","authenticated-orcid":false,"given":"Asli","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"1","key":"609_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311. https:\/\/doi.org\/10.1002\/art.37715.","journal-title":"Arthritis Rheum."},{"key":"609_CR2","first-page":"1152","volume":"105","author":"H Behcet","year":"1937","unstructured":"Behcet H. Uber rezidivierende aphthose, durch ein Virus verursachte Geschwure, am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr. 1937;105:1152\u20137.","journal-title":"Dermatol Wochenschr"},{"issue":"6","key":"609_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1346-8138.13381","volume":"43","author":"E Alpsoy","year":"2016","unstructured":"Alpsoy E. Beh\u00e7et\u2019s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620\u201332. https:\/\/doi.org\/10.1111\/1346-8138.13381.","journal-title":"J Dermatol."},{"issue":"2","key":"609_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/1756-185x.13771","volume":"23","author":"G Mumcu","year":"2020","unstructured":"Mumcu G, Yay M, Aksoy A, Ta\u015f MN, Arma\u011fan B, Sar\u0131 A, et al. Predictive factors for work-day loss in Beh\u00e7et\u2019s syndrome: A multi-center study. Int J Rheum Dis. 2020;23(2):240\u20136. https:\/\/doi.org\/10.1111\/1756-185x.13771.","journal-title":"Int J Rheum Dis."},{"issue":"5","key":"609_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2133.2007.08116.x","volume":"157","author":"E Alpsoy","year":"2007","unstructured":"Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A. Clinical features and natural course of Beh\u00e7et\u2019s disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157(5):901\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08116.x.","journal-title":"Br J Dermatol."},{"issue":"1","key":"609_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60\u201376. https:\/\/doi.org\/10.1097\/00005792-200301000-00006.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"609_CR7","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00296-015-3310-5","volume":"35","author":"N Ugurlu","year":"2015","unstructured":"Ugurlu N, Bozkurt S, Bacanli A, Akman-Karakas A, Uzun S, Alpsoy E. The natural course and factors affecting severity of Beh\u00e7et\u2019s disease: a single-center cohort of 368 patients. Rheumatol Int. 2015;35(12):2103\u20137. https:\/\/doi.org\/10.1007\/s00296-015-3310-5.","journal-title":"Rheumatol Int."},{"issue":"4","key":"609_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3349\/ymj.2007.48.4.573","volume":"48","author":"E Alpsoy","year":"2007","unstructured":"Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet\u2019s disease. Yonsei Med J. 2007;48(4):573\u201385. https:\/\/doi.org\/10.3349\/ymj.2007.48.4.573.","journal-title":"Yonsei Med J."},{"key":"609_CR9","first-page":"509","volume":"12","author":"O Demirhindi","year":"1981","unstructured":"Demirhindi O, Yaz\u0131c\u0131 H, Biny\u0131ld\u0131z P. Silivri Fener k\u00f6y\u00fc y\u00f6resinde Beh\u00e7et hastal\u0131\u011f\u0131 s\u0131kl\u0131\u011f\u0131 ve bu hastal\u0131\u011f\u0131n toplum i\u00e7erisinde taranmas\u0131nda kullan\u0131labilecek bir y\u00f6ntem. Cerrahpa\u015fa T\u0131p Fak\u00fcltesi Dergisi. 1981;12:509\u201314.","journal-title":"Cerrahpa\u015fa T\u0131p Fak\u00fcltesi Dergisi"},{"issue":"5","key":"609_CR10","first-page":"820","volume":"15","author":"S Yurdakul","year":"1988","unstructured":"Yurdakul S, G\u00fcnaydin I, T\u00fcz\u00fcn Y, Tankurt N, Pazarli H, Ozyazgan Y, Yazici H. The prevalence of Beh\u00e7et\u2019s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15(5):820\u20132.","journal-title":"J Rheumatol."},{"key":"609_CR11","unstructured":"Acar MA, Akbaba M, Yalaz M. \u00c7ukurova b\u00f6lgesinde Beh\u00e7et hastal\u0131\u011f\u0131 prevalans\u0131. Deri ve Z\u00fchrevi Hastal\u0131klarda Yenilikler Simpozyumu 1989;272-5."},{"issue":"5","key":"609_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1076\/opep.9.5.325.10338","volume":"9","author":"A Idil","year":"2002","unstructured":"Idil A, G\u00fcrler A, Boyvat A, Caliskan D, Ozdemir O, Isik A, et al. The prevalence of Beh\u00e7et\u2019s disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara. Turkey Ophthalmic Epidemiol. 2002;9(5):325\u201331. https:\/\/doi.org\/10.1076\/opep.9.5.325.10338.","journal-title":"Turkey. Ophthalmic Epidemiol."},{"issue":"10","key":"609_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","volume":"42","author":"G Azizlerli","year":"2003","unstructured":"Azizlerli G, K\u00f6se AA, Sarica R, G\u00fcl A, Tutkun IT, Kula\u00e7 M, Tun\u00e7 R, Urgancio\u011flu M, Di\u015f\u00e7i R. Prevalence of Beh\u00e7et\u2019s disease in Istanbul, Turley. Int J Dermatol. 2003;42(10):803\u20136. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01893.x.","journal-title":"Int J Dermatol."},{"issue":"4 Suppl 34","key":"609_CR14","first-page":"S53","volume":"22","author":"N Cakir","year":"2004","unstructured":"Cakir N, Dervis E, Benian O, Pamuk ON, Sonmezates N, Rahimoglu R, Tuna S, Cetin T, Sarikaya Y. Prevalence of Beh\u00e7et\u2019s disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S53\u20135.","journal-title":"Clin Exp Rheumatol."},{"issue":"3","key":"609_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/ijd.12173","volume":"54","author":"E \u00c7\u00f6lge\u00e7en","year":"2015","unstructured":"\u00c7\u00f6lge\u00e7en E, \u00d6zyurt K, Ferahba\u015f A, Borlu M, Kulluk P, \u00d6zt\u00fcrk A, \u00d6ner A\u00d6, G\u00fcn \u0130, A\u015f\u00e7\u0131o\u011flu \u00d6. The prevalence of Beh\u00e7et\u2019s disease in a city in Central Anatolia in Turkey. Int J Dermatol. 2015;54(3):286\u20139. https:\/\/doi.org\/10.1111\/ijd.12173.","journal-title":"Int J Dermatol."},{"issue":"1","key":"609_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, et al. Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 2007;57(1):171\u20138. https:\/\/doi.org\/10.1002\/art.22500.","journal-title":"Arthritis Rheum."},{"issue":"7","key":"609_CR17","first-page":"244","volume":"34","author":"T Hirohata","year":"1975","unstructured":"Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Beh\u00e7et\u2019s syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34(7):244\u20136.","journal-title":"Hawaii Med J."},{"issue":"5 Suppl 42","key":"609_CR18","first-page":"S125","volume":"24","author":"NG Papoutsis","year":"2006","unstructured":"Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, K\u00f6tter I, Krause L, et al. Prevalence of Adamantiades-Beh\u00e7et\u2019s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S125 (Erratum in: Clin Exp Rheumatol. 2007 May-Jun;25(3):507-8).","journal-title":"Clin Exp Rheumatol."},{"issue":"10","key":"609_CR19","first-page":"471","volume":"73","author":"JH Kappen","year":"2015","unstructured":"Kappen JH, van Dijk EH, Baak-Dijkstra M, van Daele PL, Lam-Tse WK, van Hagen PM, van Laar JA. Beh\u00e7et\u2019s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth J Med. 2015;73(10):471\u20137.","journal-title":"Neth J Med."},{"issue":"12","key":"609_CR20","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/art.24149","volume":"58","author":"A Mahr","year":"2008","unstructured":"Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, Lhote F, Ramanoelina J, Coste J, Guillevin L. Population-based prevalence study of Beh\u00e7et\u2019s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951\u20139. https:\/\/doi.org\/10.1002\/art.24149.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"609_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","volume":"42","author":"U Tursen","year":"2003","unstructured":"Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Beh\u00e7et\u2019s disease. Int J Dermatol. 2003;42(5):346\u201351. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01741.x.","journal-title":"Int J Dermatol."},{"issue":"2","key":"609_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/md.0b013e318211bf28","volume":"90","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Beh\u00e7et disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125\u201332. https:\/\/doi.org\/10.1097\/md.0b013e318211bf28.","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"609_CR23","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3748\/wjg.v21.i13.3801","volume":"21","author":"W Skef","year":"2015","unstructured":"Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Beh\u00e7et\u2019s disease: a review. World J Gastroenterol. 2015;21(13):3801\u201312. https:\/\/doi.org\/10.3748\/wjg.v21.i13.3801.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"609_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keu247","volume":"54","author":"NG Bonitsis","year":"2015","unstructured":"Bonitsis NG, Luong Nguyen LB, LaValley MP, Papoutsis N, Altenburg A, K\u00f6tter I, et al. Gender-specific differences in Adamantiades-Beh\u00e7et\u2019s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology (Oxford). 2015;54(1):121\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keu247.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"609_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/ard.43.6.783","volume":"43","author":"H Yazici","year":"1984","unstructured":"Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Behcet\u2019s syndrome. Ann Rheum Dis. 1984;43(6):783\u20139. https:\/\/doi.org\/10.1136\/ard.43.6.783.","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 36","key":"609_CR26","first-page":"46","volume":"22","author":"N Pipitone","year":"2004","unstructured":"Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Beh\u00e7et\u2019s disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol. 2004;22(6 Suppl 36):46\u201351.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"609_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3346\/jkms.2003.18.2.231","volume":"18","author":"DS Bang","year":"2003","unstructured":"Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on patients with Beh\u00e7et\u2019s disease in Korea. J Korean Med Sci. 2003;18(2):231\u20135. https:\/\/doi.org\/10.3346\/jkms.2003.18.2.231.","journal-title":"J Korean Med Sci."},{"issue":"17","key":"609_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/nejm199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341(17):1284\u201391. https:\/\/doi.org\/10.1056\/nejm199910213411707.","journal-title":"N Engl J Med."},{"issue":"1","key":"609_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard.43.1.74","volume":"43","author":"H Yazici","year":"1984","unstructured":"Yazici H, Chamberlain MA, T\u00fcz\u00fcn Y, Yurdakul S, M\u00fcft\u00fcoglu A. A comparative study of the pathergy reaction among Turkish and British patients with Beh\u00e7et\u2019s disease. Ann Rheum Dis. 1984;43(1):74\u20135. https:\/\/doi.org\/10.1136\/ard.43.1.74.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"609_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/ard.43.1.70","volume":"43","author":"PG Davies","year":"1984","unstructured":"Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ. The pathergy test and Beh\u00e7et\u2019s syndrome in Britain. Ann Rheum Dis. 1984;43(1):70\u20133. https:\/\/doi.org\/10.1136\/ard.43.1.70.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"609_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1046\/j.1365-4362.1998.00474.x","volume":"37","author":"T Ergun","year":"1998","unstructured":"Ergun T, G\u00fcrb\u00fcz O, Harvell J, Jorizzo J, White W. The histopathology of pathergy: a chronologic study of skin hyperreactivity in Beh\u00e7et\u2019s disease. Int J Dermatol. 1998;37(12):929\u201333. https:\/\/doi.org\/10.1046\/j.1365-4362.1998.00474.x.","journal-title":"Int J Dermatol."},{"issue":"8","key":"609_CR32","first-page":"747","volume":"109","author":"JL Jorizzo","year":"1985","unstructured":"Jorizzo JL, Solomon AR, Cavallo T. Beh\u00e7et\u2019s syndrome. Immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up. Arch Pathol Lab Med. 1985;109(8):747\u201351.","journal-title":"Arch Pathol Lab Med."},{"issue":"1","key":"609_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000081480","volume":"210","author":"E Alpsoy","year":"2005","unstructured":"Alpsoy E, Elpek GO, Yilmaz F, Ciftcioglu MA, Akman A, Uzun S, Karakuzu A. Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Beh\u00e7et\u2019s disease. Dermatology. 2005;210(1):31\u20135. https:\/\/doi.org\/10.1159\/000081480.","journal-title":"Dermatology"},{"issue":"5","key":"609_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1365-2230.2005.01846.x","volume":"30","author":"N Sallakci","year":"2005","unstructured":"Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O. CTLA-4 gene 49A\/G polymorphism in Turkish patients with Beh\u00e7et\u2019s disease. Clin Exp Dermatol. 2005;30(5):546\u201350. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01846.x.","journal-title":"Clin Exp Dermatol."},{"issue":"10","key":"609_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","volume":"10","author":"P Leccese","year":"2019","unstructured":"Leccese P, Alpsoy E. Beh\u00e7et\u2019s Disease: an overview of etiopathogenesis. Front Immunol. 2019;10(10):1067. https:\/\/doi.org\/10.3389\/fimmu.2019.01067.","journal-title":"Front Immunol."},{"key":"609_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa682","author":"HS Ahn","year":"2020","unstructured":"Ahn HS, Kim HJ, Kazmi SZ, Kang T, Jun JB, Kang MJ, et al. Familial risk of Beh\u00e7et\u2019s disease among first-degree relatives: a population-based aggregation study in Korea. Rheumatology (Oxford). 2020. https:\/\/doi.org\/10.1093\/rheumatology\/keaa682.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"609_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000068888","volume":"206","author":"E Alpsoy","year":"2003","unstructured":"Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis CC. Serum of patients with Beh\u00e7et\u2019s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology. 2003;206(3):225\u201332. https:\/\/doi.org\/10.1159\/000068888.","journal-title":"Dermatology"},{"key":"609_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.biopha.2017.04.106","volume":"91","author":"S Alipour","year":"2017","unstructured":"Alipour S, Nouri M, Sakhinia E, Samadi N, Roshanravan N, Ghavami A, et al. Epigenetic alterations in chronic disease focusing on Beh\u00e7et\u2019s disease: Review. Biomed Pharmacother. 2017;91:526\u201333. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.106.","journal-title":"Biomed Pharmacother."},{"issue":"4 Suppl 45","key":"609_CR39","first-page":"S27","volume":"25","author":"G Mumcu","year":"2007","unstructured":"Mumcu G, Inanc N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S27-33.","journal-title":"Clin Exp Rheumatol."},{"issue":"8","key":"609_CR40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/j.1468-3083.2008.02678.x","volume":"22","author":"A Akman","year":"2008","unstructured":"Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, Alpsoy E, Yegin O. Relationship between periodontal findings and the TNF-alpha Gene 1031T\/C polymorphism in Turkish patients with Beh\u00e7et\u2019s disease. J Eur Acad Dermatol Venereol. 2008;22(8):950\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02678.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"609_CR41","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/ard.60.11.996","volume":"60","author":"H Direskeneli","year":"2001","unstructured":"Direskeneli H. Beh\u00e7et\u2019s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996\u20131002. https:\/\/doi.org\/10.1136\/ard.60.11.996.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"609_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.autrev.2014.11.009","volume":"14","author":"C Consolandi","year":"2015","unstructured":"Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Beh\u00e7et\u2019s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269\u201376. https:\/\/doi.org\/10.1016\/j.autrev.2014.11.009.","journal-title":"Autoimmun Rev."},{"issue":"5","key":"609_CR43","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10067-018-04419-8","volume":"38","author":"J Shimizu","year":"2019","unstructured":"Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, et al. Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet\u2019s disease (210 characters). Clin Rheumatol. 2019;38(5):1437\u201345. https:\/\/doi.org\/10.1007\/s10067-018-04419-8.","journal-title":"Clin Rheumatol."},{"issue":"7","key":"609_CR44","doi-asserted-by":"publisher","first-page":"27150","DOI":"10.3402\/jom.v7.27150","volume":"1","author":"N Seoudi","year":"2015","unstructured":"Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F. The oral mucosal and salivary microbial community of Beh\u00e7et\u2019s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015;1(7):27150. https:\/\/doi.org\/10.3402\/jom.v7.27150.","journal-title":"J Oral Microbiol."},{"key":"609_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clim.2016.06.002","volume":"169","author":"P Coit","year":"2016","unstructured":"Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H, Sawalha AH. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Beh\u00e7et\u2019s disease. Clin Immunol. 2016;169:28\u201335. https:\/\/doi.org\/10.1016\/j.clim.2016.06.002.","journal-title":"Clin Immunol."},{"issue":"10","key":"609_CR46","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M de Menthon","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51\/B5 and the risk of Beh\u00e7et\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287\u201396. https:\/\/doi.org\/10.1002\/art.24642.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"609_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/bor.0000000000000003","volume":"26","author":"A G\u00fcl","year":"2014","unstructured":"G\u00fcl A. Genetics of Beh\u00e7et\u2019s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26(1):56\u201363. https:\/\/doi.org\/10.1097\/bor.0000000000000003.","journal-title":"Curr Opin Rheumatol."},{"issue":"3","key":"609_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ng.2551","volume":"45","author":"T Hughes","year":"2013","unstructured":"Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, D\u00fczg\u00fcn N, et al. Identification of multiple independent susceptibility loci in the HLA region in Beh\u00e7et\u2019s disease. Nat Genet. 2013;45(3):319\u201324. https:\/\/doi.org\/10.1038\/ng.2551.","journal-title":"Nat Genet."},{"issue":"8","key":"609_CR49","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et\u2019s disease. Nat Genet. 2010;42(8):698\u2013702. https:\/\/doi.org\/10.1038\/ng.625.","journal-title":"Nat Genet."},{"issue":"8","key":"609_CR50","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et\u2019s disease susceptibility loci. Nat Genet. 2010;42(8):703\u20136. https:\/\/doi.org\/10.1038\/ng.624.","journal-title":"Nat Genet."},{"issue":"2","key":"609_CR51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ng.2520","volume":"45","author":"Y Kirino","year":"2013","unstructured":"Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et\u2019s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202\u20137. https:\/\/doi.org\/10.1038\/ng.2520.","journal-title":"Nat Genet."},{"issue":"9","key":"609_CR52","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/annrheumdis-2011-200288","volume":"72","author":"YJ Lee","year":"2013","unstructured":"Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet\u2019s disease. Ann Rheum Dis. 2013;72(9):1510\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200288.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"609_CR53","doi-asserted-by":"publisher","first-page":"e0119085","DOI":"10.1371\/journal.pone.0119085","volume":"10","author":"JH Kappen","year":"2015","unstructured":"Kappen JH, Medina-Gomez C, van Hagen PM, Stolk L, Estrada K, Rivadeneira F, et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Beh\u00e7et disease. PLoS ONE. 2015;10(3):e0119085. https:\/\/doi.org\/10.1371\/journal.pone.0119085.","journal-title":"PLoS ONE"},{"issue":"24","key":"609_CR54","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1073\/pnas.1406575111","volume":"111","author":"MJ Ombrello","year":"2014","unstructured":"Ombrello MJ, Kirino Y, de Bakker PI, G\u00fcl A, Kastner DL, Remmers EF. Beh\u00e7et disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci USA. 2014;111(24):8867\u201372. https:\/\/doi.org\/10.1073\/pnas.1406575111.","journal-title":"Proc Natl Acad Sci USA."},{"key":"609_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/art.41637","author":"L Ortiz Fern\u00e1ndez","year":"2021","unstructured":"Ortiz Fern\u00e1ndez L, Coit P, Yilmaz V, Yent\u00fcr SP, Alibaz-Oner F, Aksu K, et al. Genetic association of a gain of function interferon gamma receptor 1 (IFNGR1) polymorphism and the intergenic region LNCAROD\/DKK1 with Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.41637.","journal-title":"Arthritis Rheumatol."},{"issue":"19","key":"609_CR56","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.1073\/pnas.1101262108","volume":"108","author":"G Kochan","year":"2011","unstructured":"Kochan G, Krojer T, Harvey D, Fischer R, Chen L, Vollmar M, et al. Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proc Natl Acad Sci USA. 2011;108(19):7745\u201350. https:\/\/doi.org\/10.1073\/pnas.1101262108.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"609_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/bor.0000000000000189","volume":"27","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello MJ, Kastner DL, Remmers EF. Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: genetics. Curr Opin Rheumatol. 2015;27(4):349\u201356. https:\/\/doi.org\/10.1097\/bor.0000000000000189.","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"609_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4049\/jimmunol.1300598","volume":"191","author":"E Reeves","year":"2013","unstructured":"Reeves E, Edwards CJ, Elliott T, James E. Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity. J Immunol. 2013;191(1):35\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1300598.","journal-title":"J Immunol."},{"issue":"2","key":"609_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/art.39430","volume":"68","author":"P Guasp","year":"2016","unstructured":"Guasp P, Alvarez-Navarro C, Gomez-Molina P, Mart\u00edn-Esteban A, Marcilla M, Barnea E, et al. The peptidome of Beh\u00e7et\u2019s disease-associated HLA-B*51:01 includes two subpeptidomes differentially shaped by Endoplasmic Reticulum Aminopeptidase 1. Arthritis Rheumatol. 2016;68(2):505\u201315. https:\/\/doi.org\/10.1002\/art.39430. (Erratum.In:ArthritisRheumatol.2017Mar;69(3):686.doi:10.1002\/art.39430)","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"609_CR60","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1136\/annrheumdis-2015-209059","volume":"75","author":"M Takeuchi","year":"2016","unstructured":"Takeuchi M, Ombrello MJ, Kirino Y, Erer B, Tugal-Tutkun I, Seyahi E, \u00d6zyazgan Y, Watts NR, G\u00fcl A, Kastner DL, Remmers EF. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Beh\u00e7et\u2019s disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75(12):2208\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209059.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"609_CR61","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","volume":"11","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Aydin SZ, G\u00fcl A, Mahr A, Direskeneli H. \u2019MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease. Nat Rev Rheumatol. 2015;11(12):731\u201340. https:\/\/doi.org\/10.1038\/nrrheum.2015.147.","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"609_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.13049","volume":"191","author":"M Giza","year":"2018","unstructured":"Giza M, Koftori D, Chen L, Bowness P. Is Beh\u00e7et\u2019s disease a \u201cclass 1-opathy\u201d? The role of HLA-B*51 in the pathogenesis of Beh\u00e7et\u2019s disease. Clin Exp Immunol. 2018;191(1):11\u20138. https:\/\/doi.org\/10.1111\/cei.13049.","journal-title":"Clin Exp Immunol."},{"issue":"6","key":"609_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","volume":"17","author":"A Greco","year":"2018","unstructured":"Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, de Vincentiis M, Lambiase A. Beh\u00e7et\u2019s disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567\u201375. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.006.","journal-title":"Autoimmun Rev."},{"issue":"8","key":"609_CR64","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/jid.2010.114","volume":"130","author":"NS Ekinci","year":"2010","unstructured":"Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Beh\u00e7et\u2019s disease. J Invest Dermatol. 2010;130(8):2136\u20138. https:\/\/doi.org\/10.1038\/jid.2010.114.","journal-title":"J Invest Dermatol."},{"issue":"8697","key":"609_CR65","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et's disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease. Lancet. 1990;335(8697):1078\u201380.","journal-title":"Lancet"},{"issue":"4","key":"609_CR66","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000074113","volume":"207","author":"E Alpsoy","year":"2003","unstructured":"Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B. Review of the chronology of clinical manifestations in 60 patients with Beh\u00e7et\u2019s disease. Dermatology. 2003;207(4):354\u20136. https:\/\/doi.org\/10.1159\/000074113.","journal-title":"Dermatology"},{"issue":"1","key":"609_CR67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/rheumatology\/kep350","volume":"49","author":"V Hamuryudan","year":"2010","unstructured":"Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, et al. Prognosis of Behcet\u2019s syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford). 2010;49(1):173\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kep350.","journal-title":"Rheumatology (Oxford)"},{"key":"609_CR68","doi-asserted-by":"publisher","first-page":"613432","DOI":"10.3389\/fmed.2020.613432","volume":"7","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Tsunemi Y, Kaneko F, Alpsoy E. Mucocutaneous manifestations of Beh\u00e7et\u2019s disease. Front Med. 2021;7:613432. https:\/\/doi.org\/10.3389\/fmed.2020.613432.","journal-title":"Front. Med."},{"issue":"12","key":"609_CR69","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/1346-8138.15553","volume":"47","author":"G Mumcu","year":"2020","unstructured":"Mumcu G, Yay M, Kara\u00e7ayl\u0131 \u00dc, Aksoy A, Ta\u015f MN, Arma\u011fan B, et al. Moderation analysis exploring associations between age and mucocutaneous activity in Beh\u00e7et\u2019s syndrome: A multicenter study from Turkey. J Dermatol. 2020;47(12):1403\u201310. https:\/\/doi.org\/10.1111\/1346-8138.15553.","journal-title":"J Dermatol."},{"issue":"1","key":"609_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0190-9622(99)70523-2","volume":"40","author":"JV Ghate","year":"1999","unstructured":"Ghate JV, Jorizzo JL. Behcet\u2019s disease and complex aphthosis. J Am Acad Dermatol. 1999;40(1):1\u201318. https:\/\/doi.org\/10.1016\/s0190-9622(99)70523-2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"609_CR71","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0733-8635(18)30721-6","volume":"5","author":"DT Schreiner","year":"1987","unstructured":"Schreiner DT, Jorizzo JL. Behcet\u2019s disease and complex aphthosis. Dermatol Clin. 1987;5(4):769\u201378.","journal-title":"Dermatol Clin"},{"issue":"3","key":"609_CR72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00005792-197505000-00001","volume":"54","author":"T Chajek","year":"1975","unstructured":"Chajek T, Fainaru M. Behcet\u2019s disease. Report of 41 cases and a review of the literature. Medicine (Baltimore). 1975;54(3):179\u201396. https:\/\/doi.org\/10.1097\/00005792-197505000-00001.","journal-title":"Medicine (Baltimore)"},{"issue":"3 Suppl 72","key":"609_CR73","first-page":"S32","volume":"30","author":"V Hamuryudan","year":"2012","unstructured":"Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H. Frequent oral ulceration during early disease may predict a severe disease course in males with Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S32\u20134.","journal-title":"Clin Exp Rheumatol."},{"key":"609_CR74","first-page":"S934","volume":"63","author":"FS Sacl\u0131","year":"2011","unstructured":"Sacl\u0131 FS, Seyahi E, Ugurlu S, Ozyazgan Y, Mat C, Yazici H. Some manifestations disappear earlier than others in Behcet\u2019s syndrome. Arthritis Rheumatol. 2011;63:S934.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"609_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1468-3083.2009.03435.x","volume":"24","author":"G Vaiopoulos","year":"2010","unstructured":"Vaiopoulos G, Konstantopoulou P, Evangelatos N, Kaklamanis PH. The spectrum of mucocutaneous manifestations in Adamantiades-Beh\u00e7et\u2019s disease in Greece. J Eur Acad Dermatol Venereol. 2010;24(4):434\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03435.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"609_CR76","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00296-008-0741-2","volume":"29","author":"MM El Menyawi","year":"2009","unstructured":"El Menyawi MM, Raslan HM, Edrees A. Clinical features of Behcet\u2019s disease in Egypt. Rheumatol Int. 2009;29(6):641\u20136. https:\/\/doi.org\/10.1007\/s00296-008-0741-2.","journal-title":"Rheumatol Int."},{"issue":"3","key":"609_CR77","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00296-012-2384-6","volume":"33","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, He F, Shi Y. Behcet\u2019s disease seen in China: analysis of 334 cases. Rheumatol Int. 2013;33(3):645\u20138. https:\/\/doi.org\/10.1007\/s00296-012-2384-6.","journal-title":"Rheumatol Int."},{"issue":"6","key":"609_CR78","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1111\/j.1365-2230.2009.03384.x","volume":"34","author":"SH Oh","year":"2009","unstructured":"Oh SH, Han EC, Lee JH, Bang D. Comparison of the clinical features of recurrent aphthous stomatitis and Beh\u00e7et\u2019s disease. Clin Exp Dermatol. 2009;34(6):e208\u201312. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03384.x.","journal-title":"Clin Exp Dermatol."},{"issue":"5","key":"609_CR79","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1365-4632.2006.02859.x","volume":"45","author":"MC Mat","year":"2006","unstructured":"Mat MC, Goksugur N, Engin B, Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Beh\u00e7et\u2019s syndrome: a prospective study. Int J Dermatol. 2006;45(5):554\u20136. https:\/\/doi.org\/10.1111\/j.1365-4632.2006.02859.x.","journal-title":"Int J Dermatol."},{"issue":"11","key":"609_CR80","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1046\/j.1365-4362.1998.00401.x","volume":"37","author":"E Alpsoy","year":"1998","unstructured":"Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E. A randomized, controlled and blinded study of papulopustular lesions in Turkish Beh\u00e7et\u2019s patients. Int J Dermatol. 1998;37(11):839\u201342. https:\/\/doi.org\/10.1046\/j.1365-4362.1998.00401.x.","journal-title":"Int J Dermatol."},{"issue":"5","key":"609_CR81","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1468-3083.2003.00625.x","volume":"17","author":"E Alpsoy","year":"2003","unstructured":"Alpsoy E, Uzun S, Akman A, Acar MA, Memi\u015foglu HR, Ba\u015faran E. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Beh\u00e7et\u2019s disease. J Eur Acad Dermatol Venereol. 2003;17(5):521\u20134. https:\/\/doi.org\/10.1046\/j.1468-3083.2003.00625.x.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"609_CR82","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/ard.60.11.1074","volume":"60","author":"E Diri","year":"2001","unstructured":"Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Beh\u00e7et\u2019s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001;60(11):1074\u20136. https:\/\/doi.org\/10.1136\/ard.60.11.1074.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"609_CR83","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/ard.2003.018515","volume":"63","author":"R Tunc","year":"2004","unstructured":"Tunc R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2004;63(12):1693\u20134. https:\/\/doi.org\/10.1136\/ard.2003.018515.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"609_CR84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2340\/0001555572286","volume":"72","author":"G Azizlerli","year":"1992","unstructured":"Azizlerli G, Ozarmagan G, Ovul C, Sarica R, Mustafa SO. A new kind of skin lesion in Behcet\u2019s disease: extragenital ulcerations. Acta Derm Venereol. 1992;72(4):286.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"609_CR85","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-4362.1992.tb03986.x","volume":"31","author":"O O\u011fuz","year":"1992","unstructured":"O\u011fuz O, Serdaro\u011flu S, T\u00fcz\u00fcn Y, Erdo\u011fan N, Yazici H, Sava\u015fkan H. Acute febrile neutrophilic dermatosis (Sweet\u2019s syndrome) associated with Beh\u00e7et\u2019s disease. Int J Dermatol. 1992;31(9):645\u20136. https:\/\/doi.org\/10.1111\/j.1365-4362.1992.tb03986.x.","journal-title":"Int J Dermatol."},{"issue":"1","key":"609_CR86","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2133.2007.08234.x","volume":"158","author":"JY Jung","year":"2008","unstructured":"Jung JY, Kim DY, Bang D. Leg ulcers in Beh\u00e7et\u2019s disease. Br J Dermatol. 2008;158(1):178\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08234.x.","journal-title":"Br J Dermatol."},{"issue":"5","key":"609_CR87","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11310790-000000000-00000","volume":"10","author":"SK Karado\u011fan","year":"2009","unstructured":"Karado\u011fan SK, Ba\u015fkan EB, Alkan G, Saricao\u011flu H, Tunali S. Generalized Sweet syndrome lesions associated with Beh\u00e7et disease: a true association or simply co-morbidity? Am J Clin Dermatol. 2009;10(5):331\u20135. https:\/\/doi.org\/10.2165\/11310790-000000000-00000.","journal-title":"Am J Clin Dermatol."},{"issue":"6","key":"609_CR88","first-page":"408","volume":"13","author":"CS Munro","year":"1988","unstructured":"Munro CS, Cox NH. Pyoderma gangrenosum associated with Beh\u00e7et\u2019s syndrome\u2013response to thalidomide. Clin Exp Dermatol. 1988;13(6):408\u201310.","journal-title":"Clin Exp Dermatol."},{"issue":"4","key":"609_CR89","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2340\/00015555-0221","volume":"87","author":"JW Kim","year":"2007","unstructured":"Kim JW, Park JH, Lee D, Hwang SW, Park SW. Vegetative pyoderma gangrenosum in Beh\u00e7et\u2019s disease. Acta Derm Venereol. 2007;87(4):365\u20137. https:\/\/doi.org\/10.2340\/00015555-0221.","journal-title":"Acta Derm Venereol."},{"issue":"2 Pt 2","key":"609_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0190-9622(89)80027-1","volume":"21","author":"SH Lee","year":"1989","unstructured":"Lee SH, Chung KY, Lee WS, Lee S. Beh\u00e7et\u2019s syndrome associated with bullous necrotizing vasculitis. J Am Acad Dermatol. 1989;21(2 Pt 2):327\u201330. https:\/\/doi.org\/10.1016\/s0190-9622(89)80027-1.","journal-title":"J Am Acad Dermatol."},{"issue":"3 Pt 1","key":"609_CR91","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0190-9622(89)80234-8","volume":"21","author":"F Cornelis","year":"1989","unstructured":"Cornelis F, Sigal-Nahum M, Gaulier A, Bleichner G, Sigal S. Beh\u00e7et\u2019s disease with severe cutaneous necrotizing vasculitis: response to plasma exchange\u2013report of a case. J Am Acad Dermatol. 1989;21(3 Pt 1):576\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(89)80234-8.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"609_CR92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00296-006-0155-y","volume":"27","author":"A Ate\u015f","year":"2006","unstructured":"Ate\u015f A, Karaaslan Y, A\u015flar ZO. A case of Beh\u00e7et\u2019s disease associated with necrotizing small vessel vasculitis. Rheumatol Int. 2006;27(1):91\u20133. https:\/\/doi.org\/10.1007\/s00296-006-0155-y.","journal-title":"Rheumatol Int."},{"issue":"12","key":"609_CR93","first-page":"2469","volume":"25","author":"F Cantini","year":"1998","unstructured":"Cantini F, Salvarani C, Niccoli L, Senesi C, Truglia MC, Padula A, Olivieri I. Beh\u00e7et\u2019s disease with unusual cutaneous lesions. J Rheumatol. 1998;25(12):2469\u201372.","journal-title":"J Rheumatol."},{"issue":"2","key":"609_CR94","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2133.1999.02685.x","volume":"140","author":"YH Liao","year":"1999","unstructured":"Liao YH, Hsiao GH, Hsiao CH. Beh\u00e7et\u2019s disease with cutaneous changes resembling polyarteritis nodosa. Br J Dermatol. 1999;140(2):368\u20139. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02685.x.","journal-title":"Br J Dermatol."},{"issue":"3","key":"609_CR95","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-4362.1995.tb01565.x","volume":"34","author":"R King","year":"1995","unstructured":"King R, Crowson AN, Murray E, Magro CM. Acral purpuric papulonodular lesions as a manifestation of Beh\u00e7et\u2019s disease. Int J Dermatol. 1995;34(3):190\u20132. https:\/\/doi.org\/10.1111\/j.1365-4362.1995.tb01565.x.","journal-title":"Int J Dermatol."},{"issue":"8","key":"609_CR96","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/ard.52.8.619","volume":"52","author":"I Fresko","year":"1993","unstructured":"Fresko I, Yazici H, Bayrami\u00e7li M, Yurdakul S, Mat C. Effect of surgical cleaning of the skin on the pathergy phenomenon in Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 1993;52(8):619\u201320. https:\/\/doi.org\/10.1136\/ard.52.8.619.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"609_CR97","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.52.11.823","volume":"52","author":"N Dil\u015fen","year":"1993","unstructured":"Dil\u015fen N, Koni\u00e7e M, Aral O, Ocal L, Inan\u00e7 M, G\u00fcl A. Comparative study of the skin pathergy test with blunt and sharp needles in Beh\u00e7et\u2019s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis. 1993;52(11):823\u20135. https:\/\/doi.org\/10.1136\/ard.52.11.823.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"609_CR98","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11739-019-02039-x","volume":"14","author":"AS Kecici","year":"2019","unstructured":"Kecici AS, Kutlubay Z, Serdaroglu S, Tuzun Y. Pathergy testing: prospective comparison of dermatoscopic evaluation and naked eye examination. Intern Emerg Med. 2019;14(5):699\u2013703. https:\/\/doi.org\/10.1007\/s11739-019-02039-x.","journal-title":"Intern Emerg Med."},{"issue":"1","key":"609_CR99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/1756-185x.12633","volume":"20","author":"A Fatemi","year":"2017","unstructured":"Fatemi A, Shahram F, Akhlaghi M, Smiley A, Nadji A, Davatchi F. Prospective study of articular manifestations in Beh\u00e7et\u2019s disease: five-year report. Int J Rheum Dis. 2017;20(1):97\u2013102. https:\/\/doi.org\/10.1111\/1756-185x.12633.","journal-title":"Int J Rheum Dis."},{"issue":"5","key":"609_CR100","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/ard.42.5.505","volume":"42","author":"S Yurdakul","year":"1983","unstructured":"Yurdakul S, Yazici H, T\u00fcz\u00fcn Y, Pazarli H, Yal\u00e7in B, Alta\u00e7 M, et al. The arthritis of Beh\u00e7et\u2019s disease: a prospective study. Ann Rheum Dis. 1983;42(5):505\u201315. https:\/\/doi.org\/10.1136\/ard.42.5.505.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"609_CR101","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2004.03.022.","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"609_CR102","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-014-8425-z","volume":"49","author":"Y Ozyazgan","year":"2015","unstructured":"Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular involvement of Beh\u00e7et\u2019s syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(3):298\u2013306. https:\/\/doi.org\/10.1007\/s12016-014-8425-z.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"44","key":"609_CR103","doi-asserted-by":"publisher","first-page":"e1899","DOI":"10.1097\/md.0000000000001899","volume":"94","author":"E Seyahi","year":"2015","unstructured":"Seyahi E, Cakmak OS, Tutar B, Arslan C, Dikici AS, Sut N, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: An Observational Study. Medicine (Baltimore). 2015;94(44):e1899. https:\/\/doi.org\/10.1097\/md.0000000000001899.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"609_CR104","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","volume":"30","author":"E Seyahi","year":"2016","unstructured":"Seyahi E. Behcet\u2019s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30(2):279\u201395. https:\/\/doi.org\/10.1016\/j.berh.2016.08.002.","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"1","key":"609_CR105","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/md.0b013e3182428126","volume":"91","author":"D Saadoun","year":"2012","unstructured":"Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Beh\u00e7et disease: a series of 101 patients. Medicine (Baltimore). 2012;91(1):18\u201324. https:\/\/doi.org\/10.1097\/md.0b013e3182428126.","journal-title":"Medicine (Baltimore)"},{"issue":"Pt11","key":"609_CR106","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"D Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Beh\u00e7et\u2019s syndrome. Brain. 1999;122(Pt11):2183\u201394. https:\/\/doi.org\/10.1093\/brain\/122.11.2183.","journal-title":"Brain"},{"issue":"Pt 11","key":"609_CR107","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B. Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain. 1999;122(Pt 11):2171\u201382. https:\/\/doi.org\/10.1093\/brain\/122.11.2171.","journal-title":"Brain"},{"issue":"7","key":"609_CR108","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1526-4610.2005.05160.x","volume":"45","author":"S Saip","year":"2005","unstructured":"Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, Yazici H. Headache in Beh\u00e7et\u2019s syndrome. Headache. 2005;45(7):911\u20139. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05160.x.","journal-title":"Headache"},{"key":"609_CR109","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-030-24131-5_6","volume-title":"Beh\u00e7et syndrome","author":"U Uyguno\u011flu","year":"2020","unstructured":"Uyguno\u011flu U, Siva A. Beh\u00e7et syndrome and the nervous system. In: Yazici Y, Hatemi G, Seyahi E, Yazici H, editors. Beh\u00e7et syndrome. 2nd ed. Springer Nature Switzerland AG; 2020. p. 73\u201382.","edition":"2"},{"issue":"5","key":"609_CR110","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00234-003-0952-x","volume":"45","author":"O Kizilkilic","year":"2003","unstructured":"Kizilkilic O, Albayram S, Adaletli I, Ak H, Islak C, Kocer N. Endovascular treatment of Beh\u00e7et\u2019s disease-associated intracranial aneurysms: report of two cases and review of the literature. Neuroradiology. 2003;45(5):328\u201334. https:\/\/doi.org\/10.1007\/s00234-003-0952-x.","journal-title":"Neuroradiology"},{"issue":"1","key":"609_CR111","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7461\/jcen.2016.18.1.32","volume":"18","author":"S Ha","year":"2016","unstructured":"Ha S, Kim J, Kim CG, Jang SJ. Multiple intracranial aneurysms associated with Beh\u00e7et\u2019s disease. J Cerebrovasc Endovasc Neurosurg. 2016;18(1):32\u20137. https:\/\/doi.org\/10.7461\/jcen.2016.18.1.32.","journal-title":"J Cerebrovasc Endovasc Neurosurg."},{"issue":"2","key":"609_CR112","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/00004836-200003000-00006","volume":"30","author":"Y Bayraktar","year":"2000","unstructured":"Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet\u2019s disease. J Clin Gastroenterol. 2000;30(2):144\u201354. https:\/\/doi.org\/10.1097\/00004836-200003000-00006.","journal-title":"J Clin Gastroenterol."},{"issue":"Suppl 2","key":"609_CR113","first-page":"65","volume":"43","author":"N Ormeci","year":"2009","unstructured":"Ormeci N. Gastrointestinal involvement in Behcet\u2019s disease. Turkderm. 2009;43(Suppl 2):65\u20138.","journal-title":"Turkderm"},{"issue":"1","key":"609_CR114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/md.0b013e3182428f49","volume":"91","author":"G Geri","year":"2012","unstructured":"Geri G, Wechsler B, Thi Huong DL, Isnard R, Piette JC, Amoura Z, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91(1):25\u201334. https:\/\/doi.org\/10.1097\/md.0b013e3182428f49.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"609_CR115","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1378\/chest.118.2.479","volume":"118","author":"N Mogulkoc","year":"2000","unstructured":"Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Beh\u00e7et\u2019s disease: a systematic review. Chest. 2000;118(2):479\u201387. https:\/\/doi.org\/10.1378\/chest.118.2.479.","journal-title":"Chest"},{"issue":"11","key":"609_CR116","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/rheumatology\/keh359","volume":"43","author":"E Seyahi","year":"2004","unstructured":"Seyahi E, Memisoglu E, Hamuryudan V, Tepe S, Aker UT, Balci H, Ongen Z, Yurdakul S, Yazici H. Coronary atherosclerosis in Beh\u00e7et\u2019s syndrome: a pilot study using electron-beam computed tomography. Rheumatology (Oxford). 2004;43(11):1448\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/keh359.","journal-title":"Rheumatology (Oxford)"},{"issue":"3 Suppl 72","key":"609_CR117","first-page":"S27","volume":"30","author":"C Yue","year":"2012","unstructured":"Yue C, Li J, Li M, Zhang F, Zhao D, Cui Q. Cardiac mass in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S27-31.","journal-title":"Clin Exp Rheumatol."},{"issue":"4 Suppl 60","key":"609_CR118","first-page":"S82","volume":"28","author":"K Sacr\u00e9","year":"2010","unstructured":"Sacr\u00e9 K, Ducrocq G, Hernigou A, Laissy JP, Papo T. Unusual cardiovascular events in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S82\u20135.","journal-title":"Clin Exp Rheumatol."},{"issue":"3","key":"609_CR119","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/pas.0b013e31814b23da","volume":"32","author":"I Lee","year":"2008","unstructured":"Lee I, Park S, Hwang I, Kim MJ, Nah SS, Yoo B, Song JK. Cardiac Beh\u00e7et disease presenting as aortic valvulitis\/aortitis or right heart inflammatory mass: a clinicopathologic study of 12 cases. Am J Surg Pathol. 2008;32(3):390\u20138. https:\/\/doi.org\/10.1097\/pas.0b013e31814b23da.","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"609_CR120","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1464-410x.1991.tb15230.x","volume":"67","author":"Z Kirkali","year":"1991","unstructured":"Kirkali Z, Yigitbasi O, Sasmaz R. Urological aspects of Beh\u00e7et\u2019s disease. Br J Urol. 1991;67(6):638\u20139. https:\/\/doi.org\/10.1111\/j.1464-410x.1991.tb15230.x.","journal-title":"Br J Urol."},{"issue":"5","key":"609_CR121","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/sarh.2002.31721","volume":"31","author":"T Akpolat","year":"2002","unstructured":"Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Beh\u00e7et\u2019s disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31(5):317\u201337. https:\/\/doi.org\/10.1053\/sarh.2002.31721.","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"609_CR122","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.semarthrit.2007.11.001","volume":"38","author":"T Akpolat","year":"2008","unstructured":"Akpolat T, Dilek M, Aksu K, Keser G, Toprak O, Cirit M, et al. Renal Beh\u00e7et\u2019s disease: an update. Semin Arthritis Rheum. 2008;38(3):241\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.11.001.","journal-title":"Semin Arthritis Rheum."},{"key":"609_CR123","doi-asserted-by":"publisher","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD). The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-47. https:\/\/doi.org\/10.1111\/jdv.12107","DOI":"10.1111\/jdv.12107"},{"key":"609_CR124","doi-asserted-by":"crossref","unstructured":"Evaluation of diagnostic ('classification') criteria in Beh\u00e7et's disease--towards internationally agreed criteria. The International Study Group for Beh\u00e7et's disease. Br J Rheumatol. 1992;31(5):299-308.","DOI":"10.1093\/rheumatology\/31.5.299"},{"issue":"2","key":"609_CR125","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10067-013-2411-3","volume":"34","author":"F Davatchi","year":"2015","unstructured":"Davatchi F, Abdollahi BS, Chams-Davatchi C, Shahram F, Nadji A, Shams H, Faezi T, Akhlaghi M, Ashofteh F, Mataji M, Moradi K, Mohtasham N. Validation of the revised International Criteria for Behcet\u2019s Disease (ICBD) in Iran. Clin Rheumatol. 2015;34(2):315\u201320. https:\/\/doi.org\/10.1007\/s10067-013-2411-3.","journal-title":"Clin Rheumatol."},{"key":"609_CR126","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2014.01.014","volume":"48\u201349","author":"H Yazici","year":"2014","unstructured":"Yazici H, Yazici Y. Criteria for Beh\u00e7et\u2019s disease with reflections on all disease criteria. J Autoimmun. 2014;48\u201349:104\u20137. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.014.","journal-title":"J Autoimmun."},{"issue":"1","key":"609_CR127","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s0190-9622(85)70147-8","volume":"13","author":"JL Jorizzo","year":"1985","unstructured":"Jorizzo JL, Taylor RS, Schmalstieg FC, Solomon AR Jr, Daniels JC, Rudloff HE, et al. Complex aphthosis: a forme fruste of Beh\u00e7et\u2019s syndrome? J Am Acad Dermatol. 1985;13(1):80\u20134. https:\/\/doi.org\/10.1016\/s0190-9622(85)70147-8.","journal-title":"J Am Acad Dermatol."},{"key":"609_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JEP.S265645","volume":"13","author":"BC Bozca","year":"2021","unstructured":"Bozca BC, Alpsoy E. Experimental therapeutic solutions for Behcet\u2019s disease. J Exp Pharmacol. 2021;13:1\u201319.","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"609_CR129","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","volume":"74","author":"D van der Heijde","year":"2015","unstructured":"van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206350.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"609_CR130","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0030-4220(91)90553-o","volume":"72","author":"TF Meiller","year":"1991","unstructured":"Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol. 1991;72(4):425\u20139. https:\/\/doi.org\/10.1016\/0030-4220(91)90553-o.","journal-title":"Oral Surg Oral Med Oral Pathol."},{"issue":"4","key":"609_CR131","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/sj.bdj.4803798","volume":"141","author":"M Addy","year":"1976","unstructured":"Addy M, Carpenter R, Roberts WR. Management of recurrent aphthous ulceration. A trial of chlorhexidine gluconate gel. Br Dent J. 1976;141(4):118\u201320. https:\/\/doi.org\/10.1038\/sj.bdj.4803798.","journal-title":"Br Dent J."},{"issue":"6","key":"609_CR132","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.tripleo.2003.08.024","volume":"96","author":"AR Kerr","year":"2003","unstructured":"Kerr AR, Drexel CA, Spielman AI. The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(6):685\u201394. https:\/\/doi.org\/10.1016\/j.tripleo.2003.08.024.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"1","key":"609_CR133","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1754-4505.2008.00006.x","volume":"28","author":"M Gorsky","year":"2008","unstructured":"Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dentist. 2008;28(1):27\u201331. https:\/\/doi.org\/10.1111\/j.1754-4505.2008.00006.x.","journal-title":"Spec Care Dentist."},{"issue":"6","key":"609_CR134","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1600-0714.1978.tb01605.x","volume":"7","author":"EA Graykowski","year":"1978","unstructured":"Graykowski EA, Kingman A. Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol. 1978;7(6):376\u201382. https:\/\/doi.org\/10.1111\/j.1600-0714.1978.tb01605.x.","journal-title":"J Oral Pathol."},{"issue":"8","key":"609_CR135","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1600-051x.1996.tb00609.x","volume":"23","author":"AB Skaare","year":"1996","unstructured":"Skaare AB, Herlofson BB, Barkvoll P. Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol. 1996;23(8):778\u201381. https:\/\/doi.org\/10.1111\/j.1600-051x.1996.tb00609.x.","journal-title":"J Clin Periodontol."},{"issue":"4","key":"609_CR136","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tripleo.2005.12.014","volume":"102","author":"J Liu","year":"2006","unstructured":"Liu J, Zeng X, Chen Q, Cai Y, Chen F, Wang Y, Zhou H, Lin M, Shi J, Wang Z, Zhang Y. An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(4):475\u201381. https:\/\/doi.org\/10.1016\/j.tripleo.2005.12.014.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"4","key":"609_CR137","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/s1079-2104(97)90031-7","volume":"84","author":"MA Saxen","year":"1997","unstructured":"Saxen MA, Ambrosius WT, Rehemtula al=KF, Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):356\u201361. https:\/\/doi.org\/10.1016\/s1079-2104(97)90031-7.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"2","key":"609_CR138","first-page":"75","volume":"14","author":"MM Fani","year":"2012","unstructured":"Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee SS. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet\u2019s syndrome. Iran Red Crescent Med J. 2012;14(2):75\u20138.","journal-title":"Iran Red Crescent Med J."},{"issue":"5","key":"609_CR139","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archderm.135.5.529","volume":"135","author":"E Alpsoy","year":"1999","unstructured":"Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh\u00e7et disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999;135(5):529\u201332. https:\/\/doi.org\/10.1001\/archderm.135.5.529.","journal-title":"Arch Dermatol."},{"key":"609_CR140","unstructured":"Hatemi G, Yurttas B, Kutlubay Z, Cote T, Derkunt S, Yazici Y, et al. Pentoxifylline gel for oral ulcers in patients with Beh\u00e7et\u2019s syndrome [abstract]. Arthritis Rheumatol. 2019;71(supl 10)."},{"issue":"2","key":"609_CR141","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000182257","volume":"218","author":"O K\u00f6se","year":"2009","unstructured":"K\u00f6se O, Din\u00e7 A, Sim\u015fek I. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Beh\u00e7et\u2019s disease. Dermatology. 2009;218(2):140\u20135. https:\/\/doi.org\/10.1159\/000182257.","journal-title":"Dermatology"},{"issue":"3","key":"609_CR142","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1756-185x.2010.01531.x","volume":"13","author":"C Chams-Davatchi","year":"2010","unstructured":"Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet\u2019s disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13(3):253\u20138. https:\/\/doi.org\/10.1111\/j.1756-185x.2010.01531.x.","journal-title":"Int J Rheum Dis."},{"key":"609_CR143","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/871019","author":"E Alpsoy","year":"2012","unstructured":"Alpsoy E. New evidence-based treatment approach in Beh\u00e7et\u2019s disease. Patholog Res Int. 2012. https:\/\/doi.org\/10.1155\/2012\/871019.","journal-title":"Patholog Res Int."},{"issue":"10","key":"609_CR144","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00403-009-0990-2","volume":"301","author":"E Alpsoy","year":"2009","unstructured":"Alpsoy E, Akman A. Beh\u00e7et\u2019s disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301(10):693\u2013702. https:\/\/doi.org\/10.1007\/s00403-009-0990-2.","journal-title":"Arch Dermatol Res."},{"issue":"1","key":"609_CR145","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","volume":"74","author":"D van der Heijde","year":"2015","unstructured":"van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206350.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"609_CR146","first-page":"399","volume":"65","author":"E Aktulga","year":"1980","unstructured":"Aktulga E, Alta\u00e7 M, M\u00fcft\u00fcoglu A, Ozyazgan Y, Pazarli H, T\u00fcz\u00fcn Y, et al. A double blind study of colchicine in Beh\u00e7et\u2019s disease. Haematologica. 1980;65(3):399\u2013402.","journal-title":"Haematologica"},{"issue":"11","key":"609_CR147","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11%3C2686::aid-art448%3E3.0.co;2-h","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, T\u00fcz\u00fcn Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H. A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 2001;44(11):2686\u201392. https:\/\/doi.org\/10.1002\/1529-0131(200111)44:11%3C2686::aid-art448%3E3.0.co;2-h.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"609_CR148","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10165-009-0200-2","volume":"19","author":"F Davatchi","year":"2009","unstructured":"Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Beh\u00e7et\u2019s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542\u20139. https:\/\/doi.org\/10.1007\/s10165-009-0200-2.","journal-title":"Mod Rheumatol."},{"issue":"2","key":"609_CR149","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000246336","volume":"192","author":"M Calg\u00fcneri","year":"1996","unstructured":"Calg\u00fcneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Beh\u00e7et\u2019s disease. Dermatology. 1996;192(2):125\u20138. https:\/\/doi.org\/10.1159\/000246336.","journal-title":"Dermatology"},{"issue":"3","key":"609_CR150","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","volume":"45","author":"C Mat","year":"2006","unstructured":"Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H. A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford). 2006;45(3):348\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/kei165.","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"609_CR151","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/nejmoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Beh\u00e7et\u2019s syndrome\u2013a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138. https:\/\/doi.org\/10.1056\/nejmoa1408684.","journal-title":"N Engl J Med."},{"issue":"20","key":"609_CR152","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/nejmoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328. https:\/\/doi.org\/10.1056\/nejmoa1816594.","journal-title":"N Engl J Med."},{"issue":"5","key":"609_CR153","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1097\/rhu.0000000000001005","volume":"26","author":"P Moya","year":"2020","unstructured":"Moya P, Castellv\u00ed I, Magallares B, Millan M, Wilson N, Corominas H. Healing of mucocutaneous lesions with apremilast in Beh\u00e7et disease. J Clin Rheumatol. 2020;26(5):e132. https:\/\/doi.org\/10.1097\/rhu.0000000000001005.","journal-title":"J Clin Rheumatol."},{"issue":"12","key":"609_CR154","first-page":"1328","volume":"17","author":"A Saini","year":"2018","unstructured":"Saini A, Ferguson C, Salkey K. Use of apremilast for aphthous ulcers in a patient with Beh\u00e7et\u2019s syndrome. J Drugs Dermatol. 2018;17(12):1328\u20139.","journal-title":"J Drugs Dermatol."},{"issue":"12","key":"609_CR155","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","volume":"78","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Leccese P, Emmi G, Cantarini L, Lascaro N, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et\u2019s disease. Ann Rheum Dis. 2019;78(12):1736\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215437.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"609_CR156","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/rheumatology\/kez267","volume":"59","author":"G De Luca","year":"2020","unstructured":"De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of apremilast for Beh\u00e7et\u2019s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020;59(1):171\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kez267.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"609_CR157","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"609_CR158","first-page":"69","volume":"38 Suppl 127","author":"B Atienza-Mateo","year":"2020","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Gra\u00f1a J, Espinosa G, Moriano C, P\u00e9rez-Sandoval T, et al. Spanish Collaborative Group of Refractory Beh\u00e7et\u2019s Disease. Apremilast in refractory orogenital ulcers and other manifestations of Beh\u00e7et\u2019s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020;38 Suppl 127(5):69\u201375.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"609_CR159","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/nejm199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, T\u00fcz\u00fcn Y, Ozyazgan Y, Silman A, Serdaro\u011flu S, O\u011fuz V, Yurdakul S, Lovatt GE, et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med. 1990;322(5):281\u20135. https:\/\/doi.org\/10.1056\/nejm199002013220501.","journal-title":"N Engl J Med."},{"issue":"4","key":"609_CR160","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, T\u00fcz\u00fcn Y, et al. Azathioprine in Behcet\u2019s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769\u201374. https:\/\/doi.org\/10.1002\/art.1780400425.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"609_CR161","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","volume":"6","author":"A Bettiol","year":"2019","unstructured":"Bettiol A, Hatemi G, Vannozzi L, Barilaro A, Prisco D, Emmi G. Treating the different phenotypes of Beh\u00e7et\u2019s syndrome. Front Immunol. 2019;6(10):2830. https:\/\/doi.org\/10.3389\/fimmu.2019.02830.","journal-title":"Front Immunol."},{"issue":"4","key":"609_CR162","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/bf00407749","volume":"278","author":"D Tsambaos","year":"1986","unstructured":"Tsambaos D, Eichelberg D, Goos M. Beh\u00e7et\u2019s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278(4):335\u20136. https:\/\/doi.org\/10.1007\/bf00407749.","journal-title":"Arch Dermatol Res."},{"issue":"10","key":"609_CR163","first-page":"1938","volume":"25","author":"JD O'Duffy","year":"1998","unstructured":"O\u2019Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, et al. Interferon-alpha treatment of Beh\u00e7et\u2019s disease. J Rheumatol. 1998;25(10):1938\u201344.","journal-title":"J Rheumatol."},{"issue":"5","key":"609_CR164","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","volume":"243","author":"S Georgiou","year":"1998","unstructured":"Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Beh\u00e7et\u2019s disease. J Intern Med. 1998;243(5):367\u201372. https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00159.x.","journal-title":"J Intern Med."},{"issue":"4","key":"609_CR165","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/s0190-9622(94)70226-8","volume":"31","author":"E Alpsoy","year":"1994","unstructured":"Alpsoy E, Yilmaz E, Ba\u015faran E. Interferon therapy for Beh\u00e7et\u2019s disease. J Am Acad Dermatol. 1994;31(4):617\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(94)70226-8.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"609_CR166","first-page":"1098","volume":"21","author":"V Hamuryudan","year":"1994","unstructured":"Hamuryudan V, Moral F, Yurdakul S, Mat C, T\u00fcz\u00fcn Y, Ozyazgan Y, et al. Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome. J Rheumatol. 1994;21(6):1098\u2013100.","journal-title":"J Rheumatol."},{"issue":"4","key":"609_CR167","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467\u201371. https:\/\/doi.org\/10.1001\/archderm.138.4.467.","journal-title":"Arch Dermatol."},{"issue":"5","key":"609_CR168","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320\u201335. https:\/\/doi.org\/10.1016\/j.semarthrit.2003.09.010.","journal-title":"Semin Arthritis Rheum."},{"issue":"8647","key":"609_CR169","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet. 1989;1(8647):1093\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(89)92381-7.","journal-title":"Lancet"},{"key":"609_CR170","unstructured":"Assaad-Khalil S. Low-dose cyclosporin in Behcet\u2019s disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behcet\u2019s disease. In: Beh\u00e7et\u2019s disease: basic and clinical aspects. CRC Press, Boca Raton, Fla, USA, 1991.pp. 603\u2013612."},{"issue":"5 Pt 1","key":"609_CR171","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s0190-9622(97)80354-4","volume":"36","author":"O Avci","year":"1997","unstructured":"Avci O, G\u00fcrler N, G\u00fcne\u015f AT. Efficacy of cyclosporine on mucocutaneous manifestations of Beh\u00e7et\u2019s disease. J Am Acad Dermatol. 1997;36(5 Pt 1):796\u20137. https:\/\/doi.org\/10.1016\/s0190-9622(97)80354-4.","journal-title":"J Am Acad Dermatol."},{"issue":"3 Suppl 4","key":"609_CR172","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136\u201343.","journal-title":"Transplant Proc."},{"issue":"5","key":"609_CR173","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, et al. Anti-TNF therapy in the management of Behcet\u2019s disease\u2013review and basis for recommendations. Rheumatology (Oxford). 2007;46(5):736\u201341. https:\/\/doi.org\/10.1093\/rheumatology\/kem034.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"609_CR174","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98\u2013105.","journal-title":"J Rheumatol."},{"key":"609_CR175","doi-asserted-by":"publisher","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011; 41(1): 61-70. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.09.002","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"609_CR176","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, French Beh\u00e7et Network, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005.","journal-title":"J Autoimmun."},{"issue":"9","key":"609_CR177","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin Rheumatol. 2017;36(9):2063\u20139. https:\/\/doi.org\/10.1007\/s10067-017-3627-4.","journal-title":"Clin Rheumatol."},{"issue":"6","key":"609_CR178","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","volume":"27","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Emmi G, Gentileschi S, Guerriero S, Vitale A, Silvestri E, et al. Certolizumab Pegol treatment in Behcets disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031\u20135. https:\/\/doi.org\/10.1080\/14397595.2017.1285857.","journal-title":"Mod Rheumatol."},{"issue":"4","key":"609_CR179","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5152\/eurjrheum.2017.17046","volume":"4","author":"F Adeeb","year":"2017","unstructured":"Adeeb F, Ng WL, Khan MU, Devlin J, Stack AG, Fraser AD. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Beh\u00e7ets disease. Eur J Rheumatol. 2017;4(4):254\u20139. https:\/\/doi.org\/10.5152\/eurjrheum.2017.17046.","journal-title":"Eur J Rheumatol."},{"issue":"6","key":"609_CR180","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443\u201350. https:\/\/doi.org\/10.7326\/0003-4819-128-6-199803150-00004.","journal-title":"Ann Intern Med."},{"issue":"7","key":"609_CR181","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s0248-8663(99)80105-2","volume":"20","author":"B de Wazi\u00e8res","year":"1999","unstructured":"de Wazi\u00e8res B, Gil H, Magy N, Berthier S, Vuitton DA, Dupond JL. Traitement de l\u2019aphtose r\u00e9currente par thalidomide \u00e0 faible dose. Etude pilote chez 17 patients [Treatment of recurrent ulceration with low doses of thalidomide]. Pilot study in 17 patients. Rev Med Interne. 1999;20(7):567\u201370. https:\/\/doi.org\/10.1016\/s0248-8663(99)80105-2.","journal-title":"Rev Med Interne."},{"issue":"12","key":"609_CR182","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/ard.53.12.828","volume":"53","author":"JM Gardner-Medwin","year":"1994","unstructured":"Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Beh\u00e7et\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53(12):828\u201332. https:\/\/doi.org\/10.1136\/ard.53.12.828.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"609_CR183","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00126839-200304010-00002","volume":"4","author":"T Matsuda","year":"2003","unstructured":"Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Beh\u00e7et\u2019s disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19\u201328. https:\/\/doi.org\/10.2165\/00126839-200304010-00002.","journal-title":"Drugs R D."},{"issue":"5","key":"609_CR184","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","volume":"29","author":"KE Sharquie","year":"2002","unstructured":"Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Beh\u00e7et\u2019s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267\u201379. https:\/\/doi.org\/10.1111\/j.1346-8138.2002.tb00263.x.","journal-title":"J Dermatol."},{"issue":"8","key":"609_CR185","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1346-8138.2006.00128.x","volume":"33","author":"KE Sharquie","year":"2006","unstructured":"Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behcet\u2019s disease: a double blind cross-over study. J Dermatol. 2006;33(8):541\u20136. https:\/\/doi.org\/10.1111\/j.1346-8138.2006.00128.x.","journal-title":"J Dermatol."},{"issue":"4","key":"609_CR186","first-page":"e68","volume":"12","author":"KE Sharquie","year":"2013","unstructured":"Sharquie KE, Helmi RM, Noiami AA, Al-Hayani RK, Kadhom MA. The therapeutic role of isotretinoin in the management of Beh\u00e7et\u2019s disease: a single-blinded, controlled therapeutic study. J Drugs Dermatol. 2013;12(4):e68-73.","journal-title":"J Drugs Dermatol."},{"issue":"7","key":"609_CR187","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-4632.2010.04505.x","volume":"50","author":"O K\u00f6se","year":"2011","unstructured":"K\u00f6se O, Sim\u015fek I, Pay S. Mycophenolate sodium in the treatment of mucocutaneous Behcet\u2019s diseases. Int J Dermatol. 2011;50(7):895\u20136. https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04505.x.","journal-title":"Int J Dermatol."},{"issue":"12","key":"609_CR188","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003;42(12):1539\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/keg424.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"609_CR189","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3899\/jrheum.141344","volume":"42","author":"AJ Mohammad","year":"2015","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR. Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year Experience. J Rheumatol. 2015;42(10):1906\u201313. https:\/\/doi.org\/10.3899\/jrheum.141344.","journal-title":"J Rheumatol."},{"issue":"1","key":"609_CR190","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","volume":"19","author":"PC Grayson","year":"2017","unstructured":"Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, et al. Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study. Arthritis Res Ther. 2017;19(1):69. https:\/\/doi.org\/10.1186\/s13075-017-1222-3.","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"609_CR191","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology. 2014;228(3):211\u20134. https:\/\/doi.org\/10.1159\/000358125.","journal-title":"Dermatology"},{"issue":"5","key":"609_CR192","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281\u20136. https:\/\/doi.org\/10.1007\/s10067-015-3004-0.","journal-title":"Clin Rheumatol."},{"key":"609_CR193","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","volume":"82","author":"A Mirouse","year":"2017","unstructured":"Mirouse A, Barete S, Monfort JB, Resche-Rigon M, Bouyer AS, Comarmond C, et al. Ustekinumab for Beh\u00e7et\u2019s disease. J Autoimmun. 2017;82:41\u20136. https:\/\/doi.org\/10.1016\/j.jaut.2017.05.002.","journal-title":"J Autoimmun."},{"issue":"10","key":"609_CR194","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/art.40912","volume":"71","author":"A Mirouse","year":"2019","unstructured":"Mirouse A, Barete S, Desbois AC, Comarmond C, S\u00e8ne D, Domont F, et al. French Beh\u00e7et\u2019s Network. Long-Term outcome of Ustekinumab therapy for Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 2019;71(10):1727\u201332. https:\/\/doi.org\/10.1002\/art.40912.","journal-title":"Arthritis Rheumatol."},{"key":"609_CR195","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Beh\u00e7et\u2019s syndrome: a preliminary study. J Autoimmun. 2019;97:108\u201313. https:\/\/doi.org\/10.1016\/j.jaut.2018.09.002.","journal-title":"J Autoimmun."},{"issue":"5","key":"609_CR196","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/ard.62.5.492","volume":"62","author":"M Calg\u00fcneri","year":"2003","unstructured":"Calg\u00fcneri M, Ozt\u00fcrk MA, Ertenli I, Kiraz S, Apra\u015f S, Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Beh\u00e7et\u2019s disease: an open study. Ann Rheum Dis. 2003;62(5):492\u20133. https:\/\/doi.org\/10.1136\/ard.62.5.492.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"609_CR197","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/nejmoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious \u0131veitis. N Engl J Med. 2016;375(10):932\u201343. https:\/\/doi.org\/10.1056\/nejmoa1509852.","journal-title":"N Engl J Med."},{"issue":"3","key":"609_CR198","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","volume":"28","author":"E Silvestri","year":"2020","unstructured":"Silvestri E, Bitossi A, Bettiol A, Emmi G, Urban ML, Mattioli I, et al. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et\u2019s syndrome. Inflammopharmacology. 2020;28(3):711\u20138. https:\/\/doi.org\/10.1007\/s10787-020-00697-4.","journal-title":"Inflammopharmacology"},{"issue":"12","key":"609_CR199","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, et al. Comparative study of Infliximab versus Adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: National multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081\u20139. https:\/\/doi.org\/10.1002\/art.41026.","journal-title":"Arthritis Rheumatol."},{"key":"609_CR200","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200300","author":"JL Mart\u00edn-Varillas","year":"2020","unstructured":"Mart\u00edn-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Ad\u00e1n A, et al. Biological Therapy in refractory Uveitis due to Beh\u00e7et\u2019s Disease Collaborative Group. Long term follow-up and optimization of Infliximab in refractory uveitis due to Beh\u00e7et\u2019s disease. National study of 103 Caucasian patients. J Rheumatol. 2020. https:\/\/doi.org\/10.3899\/jrheum.200300.","journal-title":"J Rheumatol."},{"issue":"5","key":"609_CR201","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, G\u00fcnaydin I, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh\u00e7et disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):311\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2003.09.005.","journal-title":"Semin Arthritis Rheum."},{"issue":"7","key":"609_CR202","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, K\u00f6ksal S, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et\u2019s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.022.","journal-title":"Ophthalmology"},{"issue":"8","key":"609_CR203","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2012;64(8):2753\u201360. https:\/\/doi.org\/10.1002\/art.34450.","journal-title":"Arthritis Rheum."},{"key":"609_CR204","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","volume":"53","author":"K Tascilar","year":"2014","unstructured":"Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H, et al. Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53:2018\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/keu233.","journal-title":"Rheumatology"},{"key":"609_CR205","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","volume":"117","author":"V Hamuryudan","year":"2004","unstructured":"Hamuryudan V, Er T, Seyahi E, Akman C, T\u00fcz\u00fcn H, Fresko I, et al. Pulmonary artery aneurysms in Beh\u00e7et syndrome. Am J Med. 2004;117:867\u201370. https:\/\/doi.org\/10.1016\/j.amjmed.2004.05.027.","journal-title":"Am J Med"},{"key":"609_CR206","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1024\/0301-1526.32.2.75","volume":"32","author":"D Saba","year":"2003","unstructured":"Saba D, Saricao\u011flu H, Bayram AS, Erdo\u011fan C, Dilek K, Gebitekin C, et al. Arterial lesions in Beh\u00e7et\u2019s disease. Vasa. 2003;32:75\u201381. https:\/\/doi.org\/10.1024\/0301-1526.32.2.75.","journal-title":"Vasa"},{"key":"609_CR207","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","volume":"45","author":"V Hamuryudan","year":"2015","unstructured":"Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, Ozguler Y, et al. Pulmonary artery involvement in Beh\u00e7et \u05f3s syndrome: Effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45:369\u201373. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.008.","journal-title":"Semin Arthritis Rheum"},{"key":"609_CR208","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"N Pipitone","year":"2008","unstructured":"Pipitone N, Olivieri I, Padula A, D\u2019angelo S, Nigro A, Zuccoli G, et al. Infliximab for the treatment of Neuro-Beh\u00e7et\u2019s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285\u201390. https:\/\/doi.org\/10.1002\/art.23345.","journal-title":"Arthritis Rheum"},{"key":"609_CR209","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","volume":"30","author":"A Borhani Haghighi","year":"2011","unstructured":"Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S. Infliximab for patients with neuro-Behcet\u2019s disease: case series and literature review. Clin Rheumatol. 2011;30:1007\u201312. https:\/\/doi.org\/10.1007\/s10067-011-1726-1.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"609_CR210","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1212\/nxi.0000000000000258","volume":"3","author":"B Zeydan","year":"2016","unstructured":"Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. https:\/\/doi.org\/10.1212\/nxi.0000000000000258.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"Suppl 60","key":"609_CR211","first-page":"S119","volume":"28","author":"ASA Al-Araji","year":"2010","unstructured":"Al-Araji ASA, Saip S. Treatment of NeuroBehcet\u2019s disease with infliximab: an international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(Suppl 60):S119.","journal-title":"Clin Exp Rheumatol"},{"key":"609_CR212","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.38351","volume":"66","author":"N Noel","year":"2014","unstructured":"Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, et al. Long-term outcome of neuro-Beh\u00e7et\u2019s disease. Arthritis Rheumato. 2014;66:1306\u201314. https:\/\/doi.org\/10.1002\/art.38351.","journal-title":"Arthritis Rheumato"},{"key":"609_CR213","doi-asserted-by":"publisher","first-page":"624795","DOI":"10.3389\/fmed.2021.624795","volume":"8","author":"E Alpsoy","year":"2021","unstructured":"Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Beh\u00e7et\u2019s Disease: An algorithmic multidisciplinary approach. Front Med. 2021;8:624795. https:\/\/doi.org\/10.3389\/fmed.2021.624795.","journal-title":"Front. Med."},{"key":"609_CR214","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.24393","volume":"61","author":"D Saadoun","year":"2009","unstructured":"Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi HD, Sbai A, et al. Cerebral venous thrombosis in Behcet\u2019s disease. Arthritis Rheum. 2009;61:518\u201326. https:\/\/doi.org\/10.1002\/art.24393.","journal-title":"Arthritis Rheum"},{"key":"609_CR215","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/01.str.0000117571.76197.26","volume":"35","author":"JM Ferro","year":"2004","unstructured":"Ferro JM, Canh\u00e3o P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664\u201370. https:\/\/doi.org\/10.1161\/01.str.0000117571.76197.26.","journal-title":"Stroke"},{"key":"609_CR216","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. J Gastroenterol. 2020;55:679\u2013700. https:\/\/doi.org\/10.1007\/s00535-020-01690-y.","journal-title":"J Gastroenterol."},{"key":"609_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2017.377","volume":"33","author":"YE Park","year":"2018","unstructured":"Park YE, Cheon JH. Updated treatment strategies for intestinal Beh\u00e7et\u2019s disease. Korean J Intern Med. 2018;33:1\u201319. https:\/\/doi.org\/10.3904\/kjim.2017.377.","journal-title":"Korean J Intern Med"},{"key":"609_CR218","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10165-010-0370-y","volume":"21","author":"S Iwata","year":"2011","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et\u2019s disease. Mod Rheumatol. 2011;21:184\u201391. https:\/\/doi.org\/10.1007\/s10165-010-0370-y.","journal-title":"Mod Rheumatol"},{"key":"609_CR219","doi-asserted-by":"publisher","first-page":"940\u20138e3","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:940\u20138e3. https:\/\/doi.org\/10.1016\/j.cgh.2014.08.042.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"609_CR220","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15:395\u2013401. https:\/\/doi.org\/10.5217\/ir.2017.15.3.395.","journal-title":"Intest Res."},{"key":"609_CR221","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","volume":"69","author":"D Ma","year":"2014","unstructured":"Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet\u2019s disease. Cell Biochem Biophys. 2014;69:735\u20139. https:\/\/doi.org\/10.1007\/s12013-014-9860-4.","journal-title":"Cell Biochem Biophys."},{"key":"609_CR222","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1345\/aph.1d524","volume":"38","author":"M Sayarlioglu","year":"2004","unstructured":"Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Beh\u00e7et\u2019s disease. Ann Pharmacother. 2004;38:808\u201311. https:\/\/doi.org\/10.1345\/aph.1d524.","journal-title":"Ann Pharmacother"},{"key":"609_CR223","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ibd.20317","volume":"14","author":"K Yasui","year":"2008","unstructured":"Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Beh\u00e7et disease. Inflamm Bowel Dis. 2008;14:396\u2013400. https:\/\/doi.org\/10.1002\/ibd.20317.","journal-title":"Inflamm Bowel Dis"},{"issue":"6 Suppl 94","key":"609_CR224","first-page":"129","volume":"33","author":"I Hatemi","year":"2015","unstructured":"Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et\u2019s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):129\u201337.","journal-title":"Clin Exp Rheumatol."},{"key":"609_CR225","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition ofconsensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease: indication of anti-TNF\u03b1 monoclonal antibodies. J Gastroenterol. 2014;49:156\u201362. https:\/\/doi.org\/10.1007\/s00535-013-0872-4.","journal-title":"J Gastroenterol"},{"key":"609_CR226","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5217\/ir.2017.15.3.318","volume":"15","author":"T Hisamatsu","year":"2017","unstructured":"Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Beh\u00e7et\u2019s disease. Intest Res. 2017;15:318\u201327. https:\/\/doi.org\/10.5217\/ir.2017.15.3.318.","journal-title":"Intest Res"},{"key":"609_CR227","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","volume":"14","author":"SN Esatoglu","year":"2019","unstructured":"Esatoglu SN, Hatemi G. Update on the treatment of Beh\u00e7et\u2019s syndrome. Intern Emerg Med. 2019;14:661\u201375. https:\/\/doi.org\/10.1007\/s11739-019-02035-1.","journal-title":"Intern Emerg Med"},{"key":"609_CR228","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5582\/irdr.2015.01007","volume":"4","author":"S Demirelli","year":"2015","unstructured":"Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet\u2019s disease. Intractable Rare Dis Res. 2015;4:70\u20135. https:\/\/doi.org\/10.5582\/irdr.2015.01007.","journal-title":"Intractable Rare Dis Res."},{"key":"609_CR229","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.semarthrit.2007.11.001","volume":"38","author":"T Akpolat","year":"2008","unstructured":"Akpolat T, Dilek M, Aksu K, Keser G, Toprak O, Cirit M, et al. Renal Beh\u00e7et\u2019s disease: an update. Semin Arthritis Rheum. 2008;38:241\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.11.001.","journal-title":"Semin Arthritis Rheum."},{"key":"609_CR230","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","volume":"29","author":"Y Kato","year":"2001","unstructured":"Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001;29:335\u20136. https:\/\/doi.org\/10.1046\/j.1442-9071.2001.00445.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"609_CR231","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/s0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586\u20139. https:\/\/doi.org\/10.1016\/s0161-6420(99)90120-3.","journal-title":"Ophthalmology"},{"key":"609_CR232","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I K\u00f6tter","year":"2006","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M, Vonthein R, St\u00fcbiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications\u2013results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482\u20136. https:\/\/doi.org\/10.1007\/s10067-005-0070-8.","journal-title":"Clin Rheumatol"},{"issue":"4 Suppl 50","key":"609_CR233","first-page":"S84","volume":"26","author":"G Akman-Demir","year":"2008","unstructured":"Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Beh\u00e7et\u2019s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(4 Suppl 50):S84-90.","journal-title":"Clin Exp Rheumatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00609-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00609-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T11:17:00Z","timestamp":1699096620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00609-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":233,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00609-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"4 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"EA, AB and BCB performed the literature search and data analysis, EA and AB drafted and\/or critically revised the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}